A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) Meeting Abstract


Authors: Melero, I.; Gangadhar, T. C.; Kohrt, H. E.; Segal, N. H.; Logan, T.; Urba, W. J.; Hodi, F. S.; Ott, P. A.; Perez-Gracia, J. L.; Wolchok, J. D.; Shah, A.; Kurland, J. F.; Cohen, L. J.; Levy, R.; Wigginton, J. M.; Goldberg, S. M.
Abstract Title: A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL)
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419605401
PROVIDER: wos
Notes: Meeting Abstract: TPS3107 -- Source: Wos